Last reviewed · How we verify
NRL994
At a glance
| Generic name | NRL994 |
|---|---|
| Also known as | Low dose bowel prep (LDBP), MOVIPREP |
| Sponsor | Norgine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution (PHASE2)
- Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening (PHASE3)
- A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution (PHASE3)
- MOVIPREP® Versus NaP Pivotal Phase III Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRL994 CI brief — competitive landscape report
- NRL994 updates RSS · CI watch RSS
- Norgine portfolio CI